

Lumito signs Letter of Intent with Scientific Advisor

Lumito has signed a Letter of Intent with pathologist Paul Waring for strategic guidance regarding the market need for Lumito's products and future product development.

Paul Waring is a highly experienced pathologist with approximately 35 years of leading and global experience in the hospital sector, academia, and industry. He initiated and drove the partnership between Genentech and Ventana Medical and built large organizations around cancer biomarkers within Genentech and Astra Zeneca. He has been Director of Pathology at the Peter MacCallum Cancer Center in Melbourne and Professor and Chief Pathologist at Melbourne University. In addition to senior positions at AstraZeneca and Genentech, he has been Vice President of Medical Innovation at Roche Tissue Diagnostics.

"We are very pleased that Paul Waring sees the potential of our product and has chosen to become our first scientific advisor. We met Paul during the congress in Florence in September, and I am really glad that we already have a collaboration in place. We look forward to working with Paul and learning from his extensive experience and insights. He has been instrumental in translating new insights and innovations into clinical routine use in previous positions," says Lumito CEO Sanna Wallenborg.

"The most important things for me are belief that the technology has the potential to address an unmet clinical need and has a commercial opportunity, synergy with my other activities, absence of conflict of interest, that I like and respect the people I am working with and that there is a long term relationship so that I am genuinely engaged and part of the team and the company's success. Lumito ticks all the boxes for me," says Paul Waring.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Image Attachments

[Paul Waring](#)

Attachments

[Lumito signs Letter of Intent with Scientific Advisor](#)